Ad
related to: switching from simvastatin to atorvastatin video release dosage freeGoodRx.com has been visited by 100K+ users in the past month
109 S High St #100, Columbus, OH · Directions · (614) 224-4261
- GoodRx® Blog
Get the Latest Healthcare News
Find What Matters Most to You
- Transparent Pricing
Healthcare is confusing. We make it
simple. Use GoodRx to start saving.
- GoodRx® For Pets
GoodRx® Loves Your Pets Too!
Discover Big Savings on Pet Meds
- Phone Support Available
Our dedicated customer support team
is here to help answer questions.
- GoodRx® Blog
Search results
Results from the WOW.Com Content Network
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1] Sustained-release dosage forms are dosage ...
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine. [10] In 2005, sales were estimated at US$18.7 billion in the United States. [11] The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12]
It was a combination of the lipid-modifying drug/vitamin niacin in extended release form and the statin drug lovastatin (trade name Mevacor). [1] The combination preparation was developed by Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in 2006, subsequently transferred to AbbVie Inc. when that company was spun off from ...
Simvastatin is an effective serum lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50%. [citation needed] Simvastatin had been shown to interact with lipid-lowering transcription factor PPAR-alpha [36] and that interaction might control the neurotrophic action of the drug.
Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the lipid-lowering drug niacin and the statin drug simvastatin. [1] It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008. [2]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Ad
related to: switching from simvastatin to atorvastatin video release dosage freeGoodRx.com has been visited by 100K+ users in the past month
109 S High St #100, Columbus, OH · Directions · (614) 224-4261